Male Reproductive

Prostatitis: acute and chronic management

Clinical Overview and When to Suspect Prostatitis

— Category I: Acute bacterial prostatitis (ABP) — abrupt febrile illness

— Category II: Chronic bacterial prostatitis (CBP) — recurrent UTIs, same organism, >3 months

— Category III: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) — most common (>90% of chronic cases); IIIa inflammatory, IIIb non-inflammatory

— Category IV: Asymptomatic inflammatory prostatitis — incidental finding on biopsy or semen analysis

— Young/middle-aged man with dysuria + perineal/pelvic pain + fever → ABP

— Man with recurrent UTIs caused by the same gram-negative organism → CBP (the prostate is the reservoir)

— Chronic pelvic/perineal/ejaculatory pain >3 months without infection → CP/CPPS

— Elevated PSA or pyuria in an asymptomatic man → consider category IV before attributing to malignancy

— Men >35 or instrumentation: E. coli (most common), Klebsiella, Proteus, Pseudomonas, Enterococcus

— Men <35 with sexual exposure: N. gonorrhoeae, C. trachomatis

— Post-transrectal biopsy: fluoroquinolone-resistant E. coli is now epidemic — drives prophylaxis changes

Board pearl: A man with the third UTI in a year caused by the same E. coli strain has chronic bacterial prostatitis until proven otherwise — treat 4–6 weeks, not 3–7 days, because antibiotics must penetrate prostatic stroma.

Prostatitis = inflammation/infection of the prostate gland, affecting ~10–15% of men in their lifetime; one of the most common urologic diagnoses in men <50

NIH classification drives management — memorize all four categories:

When to suspect on Step 3:

Risk factors: indwelling/recent catheterization, recent prostate biopsy (especially transrectal), benign prostatic hyperplasia (BPH) with obstruction, unprotected anal-insertive intercourse, phimosis, urethral stricture, diabetes, immunosuppression

Microbiology pearls:

Presentation Patterns and Key History

— Sudden onset fever, chills, rigors, myalgias (sepsis-like)

— Irritative voiding: dysuria, frequency, urgency, nocturia

— Obstructive voiding: hesitancy, weak stream, incomplete emptying, occasionally acute urinary retention

— Pain: perineal, suprapubic, low back, rectal, ejaculatory

— Hematospermia or cloudy/malodorous urine

— Recurrent UTIs with intervening asymptomatic periods is the classic stem

— Mild perineal/pelvic discomfort, ejaculatory pain, post-void dribble

— Afebrile between flares; symptoms wax and wane over months to years

— ≥3 months of pelvic/perineal/genital pain without proven infection

— Pain with ejaculation is highly characteristic

— Often comorbid with IBS, anxiety/depression, pelvic floor dysfunction, fibromyalgia

— Use the NIH-CPSI (Chronic Prostatitis Symptom Index) to quantify pain, voiding, and quality-of-life domains

— Recent urinary catheterization, cystoscopy, or prostate biopsy (huge clue for ABP and resistant organisms)

— Sexual history: number of partners, condom use, insertive anal intercourse, new partner

— Prior episodes and antibiotics used (resistance patterns)

— BPH symptoms, prior urinary retention, diabetes, immunosuppression

— Medications: anticholinergics, opioids, decongestants (can precipitate retention)

Key distinction: ABP presents like urosepsis with prostate pain; CBP presents as recurrent UTI with the same organism; CP/CPPS presents as chronic pain without positive cultures. Step 3 stems separate these by fever curve, culture history, and duration.

Step 3 management: Always ask about recent transrectal prostate biopsy — post-biopsy ABP is frequently fluoroquinolone-resistant and may require carbapenem or piperacillin-tazobactam empirically.

Acute bacterial prostatitis (Category I):

Chronic bacterial prostatitis (Category II):

CP/CPPS (Category III):

Targeted history questions for Step 3 vignettes:

Physical Exam Findings (and Hemodynamic Assessment when relevant)

— Fever (often >38.5°C), tachycardia, possible hypotension if bacteremic

— Apply qSOFA/SIRS thinking — ABP can progress to urosepsis rapidly, especially in diabetics and elderly

— Assess volume status; check orthostatics if any concern for sepsis

— Suprapubic tenderness or palpable distended bladder → urinary retention (common in ABP from inflammatory obstruction)

— Costovertebral angle tenderness suggests concurrent pyelonephritis

— Inspect for urethral discharge (gonorrhea/chlamydia), phimosis, meatal stenosis

— Palpate testes/epididymis to exclude epididymo-orchitis (frequent mimic)

— ABP: prostate is exquisitely tender, warm, boggy, edematous

— CBP/CP/CPPS: prostate may be normal, mildly tender, or boggy without acute findings

— A fluctuant area suggests prostatic abscess — order imaging

Board pearl — CRITICAL SAFETY POINT: In suspected acute bacterial prostatitis, perform DRE gently and only once. Vigorous prostatic massage is contraindicated in ABP because it can precipitate bacteremia and septic shock. This is a classic Step 3 "next best step" trap — the wrong answer is "obtain expressed prostatic secretions."

CCS pearl: In a febrile man with suspected ABP on the CCS, your order set should include: vital signs q4h, blood cultures ×2, urinalysis with culture, CBC, BMP, lactate, IV access, IV fluids, and empiric IV antibiotics — before any urologic instrumentation. If retention is present, place a suprapubic catheter rather than a transurethral catheter to avoid further prostatic trauma; consult urology.

General/vital signs in ABP:

Abdominal exam:

Genitourinary exam:

Digital rectal exam (DRE) — critical and high-yield:

Bladder scan: point-of-care post-void residual to identify retention

Pelvic floor assessment in CP/CPPS: tender levator ani or pelvic floor trigger points support a myofascial component

Diagnostic Workup — Initial Labs / Imaging / ECG / Biomarkers

— Midstream urine in ABP shows pyuria, bacteriuria, positive leukocyte esterase and nitrites

— Urine culture identifies organism and sensitivities; obtain before antibiotics whenever possible

— In CBP, midstream urine may be sterile between flares — see chunk 5 for localization studies

— CBC: leukocytosis with left shift

— BMP: assess renal function (dose antibiotics; rule out obstructive AKI)

— Blood cultures × 2 if febrile, toxic, or suspected bacteremia

— Lactate if signs of sepsis

— CRP/procalcitonin can support infection but not required

— Frequently elevated in ABP (sometimes dramatically, into hundreds)

— Do NOT use PSA for cancer screening during or shortly after prostatitis — wait 4–6 weeks after resolution to recheck

— Persistently elevated PSA after treatment warrants urology referral

— NAAT for N. gonorrhoeae and C. trachomatis from first-void urine

— Offer HIV and syphilis testing

— Failure to improve within 48–72 hours of appropriate antibiotics → suspect prostatic abscess

— Severe sepsis, immunocompromise, diabetes

— Concern for upper-tract obstruction

— Transrectal ultrasound (TRUS) or CT pelvis with contrast identifies abscess; MRI most sensitive

Key distinction: Pyuria + bacteriuria + tender boggy prostate = ABP. Pyuria without bacteriuria in a young sexually active man = think urethritis (GC/CT) before prostatitis.

Step 3 management: Always recheck PSA only after complete resolution and a 4–6 week washout — a falsely elevated post-prostatitis PSA leads to unnecessary biopsies and is a known overtreatment pitfall.

Urinalysis and urine culture — the cornerstone:

Blood work in ABP:

PSA:

STI testing in men <35 or with risk factors:

Imaging — not routine, but indicated when:

Bladder scan / post-void residual: identifies retention requiring drainage

ECG: if planning fluoroquinolone in patient with QT risk factors (older age, electrolyte disturbance, other QT-prolonging meds)

Diagnostic Workup — Advanced or Confirmatory Studies

— VB1: first 10 mL voided urine → urethral flora

— VB2: midstream urine → bladder flora

— EPS: expressed prostatic secretions after prostatic massage

— VB3: post-massage urine

— >10× higher colony count or WBCs in EPS/VB3 vs VB1/VB2 = bacterial prostatitis localization

— Suspected chronic bacterial prostatitis (recurrent same-organism UTIs)

— Workup of CP/CPPS to distinguish IIIa (inflammatory, WBCs in EPS) from IIIb (non-inflammatory)

— Contraindicated in acute bacterial prostatitis (massage risks bacteremia)

— TRUS: first-line for suspected prostatic abscess; can guide drainage

— CT pelvis with IV contrast: alternative; assesses surrounding structures, periprostatic abscess, fistula

— MRI pelvis: most sensitive for abscess and for distinguishing prostatitis from prostate cancer in equivocal PSA elevation

— Suspected or confirmed prostatic abscess

— Recurrent prostatitis or treatment failure

— Urinary retention not relieved by initial drainage

— Persistently elevated PSA after treatment

— Refractory CP/CPPS for multimodal therapy

Board pearl: In a man with recurrent UTIs caused by the same E. coli, the next best test after a positive culture is post-massage urine localization (2-glass test) once acute symptoms resolve — this confirms CBP and justifies prolonged antibiotic therapy.

Key distinction: Failure to respond to 48–72 hours of appropriate IV antibiotics in ABP → image for abscess, do not simply broaden antibiotics blindly.

Meares-Stamey 4-glass test (classic, rarely fully performed today):

Simplified 2-glass (pre- and post-massage) test (Nickel): preferred in practice; comparable sensitivity, much more feasible

Indications for localization studies:

Semen culture: adjunct in CBP workup; lower specificity but useful when EPS unobtainable

Imaging — when to escalate:

Cystoscopy and urodynamics: consider in refractory CP/CPPS or to evaluate concurrent bladder outlet obstruction, stricture, or interstitial cystitis

Urology referral indications:

Risk Stratification or First-Line Management Logic

— Outpatient management acceptable if: hemodynamically stable, tolerating oral intake, no urinary retention, no immunocompromise, reliable follow-up

— Inpatient/IV therapy required if: septic, vomiting, retention, immunocompromised (diabetes, HIV, neutropenia), failed outpatient therapy, suspected resistant organism (post-biopsy, recent travel), or significant comorbidity

— Age and STI risk (<35 → cover GC/CT)

— Recent instrumentation/biopsy → cover fluoroquinolone-resistant gram-negatives and possibly Pseudomonas

— Local antibiogram and resistance patterns

— Renal function (dose adjustment)

— ABP: 4–6 weeks total (longer than typical UTI to penetrate inflamed prostate and prevent progression to CBP)

— CBP: 4–6 weeks with fluoroquinolone, or 1–3 months with TMP-SMX

— CP/CPPS: antibiotics generally NOT helpful unless localization positive; trial of 4–6 weeks acceptable in antibiotic-naive patients, then stop if no response

— Urinary, Psychosocial, Organ-specific, Infection, Neurologic/systemic, Tenderness of pelvic floor

— Treat each positive domain (e.g., alpha-blocker for urinary, CBT for psychosocial, pelvic floor PT for tenderness)

— Suprapubic catheter preferred over transurethral in ABP to avoid pressure on inflamed prostate and reduce bacteremia risk

Step 3 management: For a stable outpatient with ABP, low STI risk, and no recent instrumentation, start ciprofloxacin 500 mg PO BID or TMP-SMX DS BID for 4–6 weeks; reassess in 48–72 hours and tailor to culture. For a septic or post-biopsy patient, admit and start IV piperacillin-tazobactam or a carbapenem plus consider aminoglycoside until cultures return.

Board pearl: Treatment failures in CBP usually reflect inadequate duration, not the wrong drug — extend, don't switch reflexively.

Decision tree for acute bacterial prostatitis:

Empiric antibiotic selection driven by:

Duration of therapy — high-yield numbers:

Chronic prostatitis / CPPS — UPOINT phenotyping guides multimodal therapy:

Address urinary retention:

Pharmacotherapy — First-Line Drug Regimen

— Excellent prostatic penetration (lipophilic, weak base, concentrates in alkaline prostatic fluid)

— Ciprofloxacin 500 mg PO BID or levofloxacin 500–750 mg PO daily

— Duration: ABP 4–6 weeks; CBP 4–6 weeks

— Adverse effects to counsel: tendinopathy/rupture (Achilles), QT prolongation, aortic aneurysm/dissection risk, hypoglycemia, CNS effects, C. difficile; avoid with concurrent steroids, in elderly with aortic aneurysm

— DS (160/800) PO BID, also excellent prostatic penetration

— Duration: ABP 4–6 weeks; CBP 1–3 months

— Avoid in sulfa allergy, late pregnancy (not relevant here), G6PD deficiency; monitor renal function and potassium

— Ceftriaxone 500 mg IM × 1 (1 g if >150 kg) for gonorrhea

— Doxycycline 100 mg PO BID × 7 days for chlamydia (extend to match prostatitis duration if prostatic involvement)

— Ceftriaxone 1–2 g IV daily ± gentamicin (community-acquired, no instrumentation)

— Piperacillin-tazobactam 3.375 g IV q6h or meropenem 1 g IV q8h (healthcare-associated, post-biopsy, immunocompromised, prior resistance)

— Add vancomycin if suspected enterococcal or MRSA risk

— Step down to oral fluoroquinolone or TMP-SMX once afebrile 24–48 hours and cultures guide

— Alpha-blockers (tamsulosin 0.4 mg daily) reduce urinary symptoms and may reduce recurrence; especially useful with obstructive symptoms

— NSAIDs for pain and inflammation

— Stool softeners to reduce defecation pain

— Adequate hydration; avoid bladder irritants (caffeine, alcohol, spicy foods)

Board pearl: Beta-lactams (except ceftriaxone for severe sepsis) penetrate the non-inflamed prostate poorly — they are inadequate for chronic prostatitis. Use fluoroquinolones or TMP-SMX for chronic therapy. In acute prostatitis, the inflamed blood-prostate barrier transiently permits beta-lactam entry, which is why IV beta-lactams work initially.

Fluoroquinolones — workhorses of prostatitis therapy:

Trimethoprim-sulfamethoxazole (TMP-SMX):

STI coverage for men <35 or sexually active with risk factors:

Inpatient/IV empiric regimens for severe ABP:

Adjuncts:

Procedures / Revascularization / Invasive Management (or expanded pharmacology if non-procedural)

— Suspect when ABP fails to improve after 48–72 hours of appropriate antibiotics, in diabetics, or in immunocompromised patients

— Confirm with TRUS, CT, or MRI

— Drainage required for abscesses >1 cm:

— Transrectal or transperineal ultrasound-guided aspiration (first-line, minimally invasive)

— Transurethral resection/unroofing for larger or multiloculated abscesses

— Continue IV antibiotics 2–4 weeks, then oral to complete 4–6 weeks total

— Suprapubic catheter is preferred to avoid traumatizing inflamed prostate and provoking bacteremia

— Transurethral catheterization acceptable if suprapubic unavailable and done gently

— Trial of void after inflammation resolves (typically 5–7 days)

— Alpha-blockers: tamsulosin, alfuzosin, silodosin — for urinary domain

— 5-alpha reductase inhibitors: finasteride — modest benefit, consider with BPH overlap

— Pelvic floor physical therapy / myofascial trigger point release: for tenderness domain; strong evidence

— Neuromodulators: amitriptyline, gabapentin, pregabalin for neuropathic pain

— Cognitive behavioral therapy, stress reduction: psychosocial domain

— Phytotherapy: quercetin, pollen extract (cernilton), saw palmetto — modest evidence, low harm

— Anti-inflammatories: short-course NSAIDs

— Avoid chronic opioids — high addiction risk, low efficacy

— Sacral neuromodulation, pudendal nerve blocks, intraprostatic botulinum toxin (investigational)

— Avoid prostatectomy — does not reliably relieve CPPS pain

Step 3 management: For a man with diabetes, ABP, and persistent fever on day 3 of appropriate IV ceftriaxone, the next best step is imaging (TRUS or CT pelvis) to evaluate for prostatic abscess, not antibiotic escalation alone. If abscess >1 cm → urology consult for drainage.

CCS pearl: When ordering catheterization for retention in ABP, choose suprapubic to minimize bacteremia and patient discomfort — a frequently tested CCS micro-decision.

Prostatic abscess management:

Urinary retention in ABP:

Chronic prostatitis / CPPS — multimodal therapy (UPOINT-driven):

Refractory CP/CPPS — third-line options:

Special Populations — Elderly and Renal/Hepatic Impairment

— Higher prevalence of BPH, urinary retention, diabetes, immunosenescence → higher rates of complicated prostatitis and abscess

— Often present atypically: confusion, falls, generalized weakness rather than classic dysuria/fever

— Lower threshold for hospitalization and blood cultures

— Greater risk of fluoroquinolone toxicity: tendinopathy (especially with concomitant corticosteroids), aortic aneurysm/dissection (FDA black-box warning in elderly with known aneurysm), QT prolongation, C. difficile, delirium, hypoglycemia (especially with sulfonylureas/insulin)

— Screen for and treat coexistent BPH; alpha-blockers may help but watch for orthostatic hypotension (use uroselective tamsulosin or silodosin)

— Adjust ciprofloxacin and levofloxacin for CrCl <50 mL/min (e.g., cipro 250–500 mg q12–24h)

— TMP-SMX: avoid or reduce dose if CrCl <30; monitor potassium and creatinine closely (TMP inhibits tubular creatinine and potassium secretion)

— Aminoglycosides: nephrotoxic — use sparingly, monitor levels

— Avoid nitrofurantoin — does not achieve therapeutic prostatic concentrations

— Fluoroquinolones: minor hepatic metabolism but cases of fulminant hepatitis reported; use with caution

— Avoid moxifloxacin in severe hepatic disease

— TMP-SMX hepatotoxicity rare but possible

— Fluoroquinolone + warfarin → ↑INR

— Fluoroquinolone + sulfonylurea/insulin → hypoglycemia

— Fluoroquinolone + amiodarone/sotalol/methadone → QT

— TMP-SMX + ACEi/ARB/spironolactone → hyperkalemia

— TMP-SMX + warfarin → ↑INR

— Cations (calcium, iron, antacids, sucralfate) chelate fluoroquinolones — separate by 2–6 hours

Board pearl: An elderly man on warfarin started on ciprofloxacin or TMP-SMX needs INR rechecked within 3–5 days — a classic Step 3 ambulatory safety stem.

Step 3 management: In an elderly diabetic with ABP, choose ceftriaxone IV initially (avoids fluoroquinolone risks, covers common pathogens) and transition to oral agent based on culture sensitivities.

Elderly men (>65):

Renal impairment:

Hepatic impairment:

Drug interactions to flag in elderly polypharmacy:

Special Populations — Pregnancy, Pediatrics, or Other Demographic Subgroups

— Prostatitis is rare before puberty; when present, evaluate for anatomic anomaly (posterior urethral valves, ectopic ureter, vesicoureteral reflux)

— Obtain renal/bladder ultrasound and VCUG; pediatric urology referral

— Post-pubertal adolescents: consider sexually transmitted causes (GC/CT) and counsel on safe sex; ensure confidential STI testing per state law

— Dual coverage: ceftriaxone 500 mg IM × 1 + doxycycline 100 mg BID for STI pathogens, plus prostatitis-directed therapy if prostate involvement

— Expedited partner therapy where legally permitted

— Re-test for cure at 3 months (high re-infection rate)

— Counsel HIV PrEP candidacy

— Consider enteric pathogens (E. coli, enterococci) from insertive anal intercourse — actually broaden, not narrow, empiric coverage

— Screen for pharyngeal and rectal GC/CT, HIV, syphilis, hepatitis

— Higher rates of abscess formation and atypical pathogens (Pseudomonas, Candida, mycobacteria, Cryptococcus, CMV)

— Lower threshold for imaging and admission

— Consider fungal blood/urine cultures if persistent symptoms despite antibacterials

— Often fluoroquinolone-resistant E. coli due to widespread prophylaxis use

— Empirically cover with piperacillin-tazobactam, carbapenem, or aminoglycoside

— Drives current shift toward augmented or targeted biopsy prophylaxis (rectal swab cultures, transperineal approach)

— Polymicrobial, multidrug-resistant flora common

— Replace catheter, send urine culture from new catheter

Key distinction: Prostatitis in a prepubertal boy is not "just a UTI" — it mandates anatomic imaging to rule out underlying structural disease.

Board pearl: A 26-year-old man with prostatitis after a new sexual partner gets ceftriaxone + doxycycline empirically, not just a fluoroquinolone — STI coverage is the differentiator.

Pediatric/adolescent males:

Sexually active young men (<35):

Men who have sex with men (MSM):

Immunocompromised (HIV, transplant, neutropenic, diabetic):

Post-prostate-biopsy prostatitis:

Catheterized/long-term care residents:

Complications and Adverse Outcomes

— Urosepsis and septic shock — most feared; multiorgan failure, ICU admission, mortality up to 10–15% in elderly/immunocompromised

— Prostatic abscess — 2–18% of ABP, higher in diabetics, immunocompromised, catheterized; suspect when fever persists >48–72 hours

— Acute urinary retention from inflammatory obstruction

— Epididymo-orchitis from contiguous spread

— Pyelonephritis from ascending or hematogenous spread

— Bacteremia — risk increased by vigorous prostate massage or instrumentation

— Progression of inadequately treated ABP to chronic bacterial prostatitis (the rationale for 4–6 week therapy)

— Recurrent UTIs in CBP

— Infertility / subfertility: impaired sperm motility, leukocytospermia, ductal obstruction

— Erectile and ejaculatory dysfunction, hematospermia

— Chronic pelvic pain syndrome with major QoL impact, depression, sexual dysfunction, work disability

— Rare: prostatic calculi (nidus for recurrent infection), seminal vesicle abscess, periprostatic abscess with fistula formation

— Fluoroquinolone class: Achilles tendon rupture (especially with steroids, >60 yo), aortic dissection/aneurysm, peripheral neuropathy (can be permanent), QT prolongation, C. difficile, dysglycemia

— TMP-SMX: hyperkalemia, AKI, Stevens-Johnson syndrome, marrow suppression, drug-induced liver injury

— Catheter-associated UTI if prolonged catheterization

— Falsely elevated PSA post-prostatitis leading to unnecessary biopsy → patient harm and overdiagnosis

— Missed prostate cancer when chronically elevated PSA is attributed solely to prostatitis

Key distinction: Persistent fever after 72 hours of appropriate antibiotics in ABP = abscess until proven otherwise — image, drain, do not just escalate antibiotics.

Board pearl: A man with three episodes of "UTI" with the same E. coli over 12 months who was treated with 5-day courses each time → his complication is chronic bacterial prostatitis caused by undertreatment duration. Treat 4–6 weeks.

Acute complications of ABP:

Chronic complications:

Treatment-related complications:

Diagnostic complications:

When to Escalate Care — ICU, Consult, or Inpatient Triage

— Sepsis criteria (qSOFA ≥2, SIRS, hypotension, lactate ≥2)

— Hemodynamic instability or organ dysfunction

— Unable to tolerate oral intake/medications

— Acute urinary retention

— Immunocompromised (diabetes with poor control, HIV with low CD4, transplant, neutropenia, chemotherapy)

— Suspected or confirmed prostatic abscess

— Failed outpatient antibiotic therapy (no improvement at 48–72 hours)

— Suspected resistant organism (post-biopsy, recent fluoroquinolone exposure, healthcare-associated)

— Pregnancy of partner with potential STI exposure (logistical, not literal)

— Significant comorbidity or unreliable follow-up

— Septic shock requiring vasopressors

— Respiratory failure

— AKI requiring dialysis, severe metabolic acidosis

— Multiorgan dysfunction

— Prostatic abscess (drainage decision)

— Acute urinary retention requiring suprapubic catheter placement

— Recurrent prostatitis or CBP refractory to first course

— Suspected anatomic abnormality (stricture, calculi, obstruction)

— Refractory CP/CPPS for multimodal care

— Persistently elevated PSA after treatment → biopsy planning

— Multidrug-resistant organisms (ESBL, CRE, MDR Pseudomonas)

— Unusual pathogens (TB, fungal, atypical mycobacteria)

— Treatment failure despite susceptibility-guided therapy

— Complex immunosuppression

CCS pearl: On the CCS, a septic ABP case should trigger this rapid sequence — IV access, fluid bolus, blood cultures, lactate, urinalysis/culture, broad-spectrum IV antibiotics within 1 hour, ICU disposition if vasopressors needed, urology consult for retention or suspected abscess, imaging if no improvement at 48–72 hours.

Step 3 management: Do NOT discharge a diabetic with ABP on oral antibiotics from the ED without ensuring 24-hour follow-up — diabetes is an independent predictor of abscess and treatment failure.

Admit for inpatient management when:

ICU criteria:

Consult urology when:

Consult infectious disease when:

Pain medicine / pelvic floor PT / behavioral health for chronic CPPS

Key Differentials — Same-Category Causes

— Dysuria, frequency, urgency, suprapubic pain

— No fever, no systemic toxicity, no prostate tenderness on DRE

— 3-day antibiotic course usually sufficient; very different duration than prostatitis

— Fever, flank pain, costovertebral angle tenderness, often nausea/vomiting

— Pyuria with WBC casts

— May coexist with prostatitis; ascending or hematogenous

— Treat 7–14 days; prostate-penetrating agent preferred if prostatitis suspected concurrently

— Unilateral testicular/scrotal pain, swelling, positive Prehn sign (pain relief with elevation)

— Cremasteric reflex preserved (distinguishes from torsion)

— <35: GC/CT; >35: enteric gram-negatives — same empiric approach as prostatitis

— Discharge, dysuria without systemic features or prostate tenderness

— NAAT for GC/CT

— Obstructive symptoms, chronically enlarged firm nontender prostate, no fever

— Distinguished by exam and absence of inflammatory markers

— Hard, nodular, asymmetric prostate on DRE — distinct from boggy tender ABP

— Elevated PSA persisting after prostatitis treatment warrants biopsy

— Can rarely coexist; do not anchor

— Recurrent infections, nidus for biofilm; identified on TRUS/CT

Key distinction: Boggy + tender + febrile = ABP. Hard + nodular + painless = cancer. Enlarged + smooth + nontender + obstructive = BPH. Memorize these three DRE archetypes — Step 3 stems hinge on them.

Board pearl: Acute scrotal pain in a young man — your first concern is testicular torsion, not epididymitis or prostatitis. Get urgent Doppler ultrasound and surgical consultation; do not delay for labs.

Acute cystitis:

Pyelonephritis:

Epididymitis / epididymo-orchitis:

Urethritis:

Benign prostatic hyperplasia (BPH) with retention:

Prostate cancer:

Prostatic calculi:

Seminal vesiculitis: rare, often coexists with prostatitis; presents with hematospermia, ejaculatory pain

Key Differentials — Other-Category Causes

— Chronic pelvic pain, urinary frequency/urgency, negative cultures

— Pain worse with bladder filling, relieved by voiding

— Often confused with CP/CPPS; overlap common

— Cystoscopy with hydrodistension may show Hunner lesions

— Tender levator ani, anal sphincter, obturator internus on rectal/pelvic exam

— Major contributor to CP/CPPS — UPOINT "T" domain

— Responds to pelvic floor physical therapy

— Burning/stabbing perineal pain worse with sitting, improved standing

— Triggered by cycling or prolonged sitting

— Diagnosed by pudendal nerve block

— Herpes simplex (vesicles), syphilis (chancre), Mycoplasma genitalium (increasingly recognized)

— Endemic exposure, BCG instillation history (intravesical BCG for bladder cancer can cause granulomatous prostatitis); sterile pyuria

— Treat as GU TB if confirmed

— Lumbosacral radiculopathy, hip pathology

Key distinction: Negative cultures + chronic pelvic pain + bladder filling reproducing pain → think interstitial cystitis, not CP/CPPS — cystoscopy distinguishes.

Step 3 management: When chronic pelvic pain persists despite antibiotics and antibiotics' diagnostic trial fails, do not re-treat empirically — pivot to UPOINT-driven multimodal therapy and consider IC, pelvic floor dysfunction, and pudendal neuralgia.

Interstitial cystitis / bladder pain syndrome:

Pelvic floor dysfunction / myofascial pain:

Pudendal neuralgia:

Inguinal/femoral hernia: referred groin pain

Inflammatory bowel disease / proctitis: rectal/perineal pain with GI symptoms, blood per rectum

Anorectal pathology: anal fissure, hemorrhoids, perirectal abscess — distinguished by anoscopy

Renal/ureteral colic: flank pain radiating to groin, hematuria, no fever (uncomplicated); CT-KUB

Appendicitis (retrocecal/pelvic): can mimic with suprapubic pain; classic migration history

Sexually transmitted infections without urethritis:

Tuberculous or granulomatous prostatitis:

Prostate-related pain syndromes from referred sources:

Psychogenic/somatic pain: especially in long-standing CP/CPPS, but always exclude organic causes first

Secondary Prevention / Discharge Medications / Long-Term Plan

— Oral fluoroquinolone or TMP-SMX to complete 4–6 weeks total therapy (count from IV start)

— Continue alpha-blocker (tamsulosin) if voiding symptoms or retention occurred

— Stool softeners during course to reduce perineal discomfort

— NSAIDs PRN for pain (avoid in CKD, peptic ulcer, cardiovascular risk)

— Catheter care instructions if discharged with one; plan trial of void

— Complete full course even after symptoms resolve — undertreatment → CBP

— Hydration; avoid bladder irritants (caffeine, alcohol, spicy foods, smoking)

— Sexual activity safe once afebrile and improving; condom use during treatment

— Recognize warning signs: recurrent fever, worsening pain, retention → return to ED

— Treat underlying BPH (alpha-blocker, 5-ARI)

— Address urinary retention, stricture, calculi

— Optimize diabetes control (A1c <7% goal in most)

— Smoking cessation, weight loss

— STI prevention counseling, partner treatment, HIV PrEP if indicated

— Document with localization studies and culture

— Treat 4–6 weeks fluoroquinolone or 1–3 months TMP-SMX

— Consider low-dose suppressive antibiotics (e.g., nitrofurantoin or TMP-SMX nightly) only after urology input in refractory cases — note nitrofurantoin doesn't treat prostatitis but suppresses UTI symptoms

— Multimodal UPOINT-based approach: alpha-blockers, pelvic floor PT, neuromodulators, CBT, lifestyle, phytotherapy

— Set realistic expectations — symptom reduction, not cure

— Avoid chronic opioids and repeat antibiotic courses

Step 3 management: At hospital discharge after ABP, recheck PSA only 4–6 weeks after symptom resolution; schedule urology follow-up if PSA remains elevated to evaluate for occult malignancy. Counsel against intercourse during acute febrile phase.

Board pearl: Daily suppressive antibiotics are reserved for highly recurrent CBP after specialist input — they are not first-line and risk resistance.

Discharge regimen after ABP hospitalization:

Patient education:

Secondary prevention of recurrence:

Chronic bacterial prostatitis long-term plan:

CP/CPPS long-term plan:

Follow-Up, Monitoring Parameters, and Rehab/Counseling

— 48–72 hour clinical reassessment (phone or in-person) to confirm response — critical safety net

— 1–2 week in-person visit: symptom check, review culture/sensitivities, narrow antibiotics, address adverse effects

— End-of-treatment visit (week 4–6): confirm resolution, repeat urinalysis (test-of-cure urine culture in CBP)

— PSA recheck 4–6 weeks post-resolution if originally elevated

— Urology referral if PSA persistently elevated, recurrence, or unresolved retention

— Repeat localization study (post-massage urine) at end of therapy and at 3–6 months

— Document eradication; watch for re-emergence over 6–12 months

— Re-administer NIH-CPSI at each visit (q4–8 weeks initially) to track domain-specific response

— Adjust UPOINT-based therapies; coordinate with pelvic floor PT, behavioral health

— Fluoroquinolones: symptom check for tendon pain, dysglycemia, mental status, GI symptoms; ECG only if QT risk

— TMP-SMX: CBC, BMP (potassium, creatinine) at 1–2 weeks if prolonged course or comorbid renal/cardiac disease

— Warfarin co-prescription: INR within 3–5 days

— Diabetics on sulfonylureas/insulin + fluoroquinolone: more frequent glucose checks

— Realistic prognosis — most ABP resolves with appropriate antibiotics, but 5–10% progress to CBP

— CP/CPPS is chronic, relapsing, but manageable; emphasize multimodal therapy and active coping

— Sexual health: erectile/ejaculatory function often improves with treatment; address concerns openly

— Mental health screening (PHQ-9, GAD-7) in chronic patients — high comorbidity with depression/anxiety

— Pelvic floor PT for CP/CPPS with tenderness

— Stress reduction, mindfulness, exercise, smoking cessation

— Avoid prolonged sitting (use cushion), bicycling adjustments if symptomatic

Step 3 management: A 48–72 hour reassessment after initiating outpatient ABP therapy is a non-negotiable transition-of-care milestone — telephone visit acceptable, but document response and red-flag instructions in the chart.

Follow-up cadence after ABP:

Follow-up after CBP treatment:

Follow-up for CP/CPPS:

Monitoring parameters during therapy:

Counseling content:

Rehabilitation/lifestyle:

Ethical, Legal, and Patient Safety Considerations

— Disclose risks: bleeding, infection (1–5%, including resistant ABP and sepsis), urinary retention, hematospermia, erectile dysfunction

— Discuss alternative imaging-guided (transperineal) approaches with lower infection risk

— Discuss shared decision-making for PSA screening per USPSTF (grade C for 55–69) before any biopsy cascade

— Confirmed gonorrhea, chlamydia, syphilis, HIV are reportable to public health in all states

— Discuss partner notification and expedited partner therapy where legally permitted (varies by state)

— Confidentiality protections for adolescents under state-specific minor consent laws

— Avoid empiric fluoroquinolones for uncomplicated cystitis (collateral damage, C. diff, resistance, FDA warnings)

— Avoid repeated empiric antibiotic courses for CP/CPPS without microbiologic evidence — drives resistance and harm

— Document indication and planned duration; de-escalate based on cultures

— ED-to-outpatient handoff: ensure 48–72 hour follow-up, confirm pharmacy fill, review culture results and adjust within 72 hours

— Hospital-to-home: written instructions, medication reconciliation, recognize warning signs, contact information for after-hours

— Closed-loop on pending cultures at discharge — a leading malpractice and patient-safety failure mode

— Fluoroquinolones can cause CNS effects, dysglycemia; counsel before operating machinery

— Higher rates of complicated prostatitis in uninsured/underinsured and racial/ethnic minorities — facilitate access to follow-up and pelvic floor PT

— Counsel on potential fertility impact in young men; offer semen analysis if persistent infertility concerns

— DRE findings, exam consent, antibiotic rationale, follow-up plan, return precautions

Step 3 management: A safe discharge after ED treatment of ABP requires: prescription dispensed, explicit 48–72 hour follow-up, written warning signs, plan for culture review and antibiotic adjustment, and documentation of all of these — a classic Step 3 patient-safety stem favors the answer that closes the culture-result loop.

Informed consent for prostate biopsy and procedures:

Mandatory STI reporting:

Antibiotic stewardship:

Transition-of-care safety:

Driving and occupational safety:

Equity and access:

Sexual and reproductive ethics:

Documentation:

High-Yield Associations and Rapid-Fire Clinical Facts

Board pearl: "Boggy, tender, warm prostate + fever + dysuria" = ABP; the answer is start antibiotics, NOT prostate massage, NOT immediate biopsy, NOT PSA.

Key distinction: Tender boggy prostate = ABP. Hard nodular prostate = cancer. Smooth enlarged nontender = BPH. Normal prostate + chronic pelvic pain = CP/CPPS.

Most common pathogen overall: E. coli

Most common pathogen <35 with sexual exposure: N. gonorrhoeae, C. trachomatis

Post-transrectal biopsy pathogen: fluoroquinolone-resistant E. coli

Most common NIH category: III (CP/CPPS, >90% of chronic prostatitis)

DRE contraindication: vigorous massage in ABP (bacteremia risk)

Antibiotic of choice for chronic prostatitis: fluoroquinolone or TMP-SMX (lipophilic, alkaline-trapping)

Why beta-lactams fail in CBP: poor prostatic penetration through non-inflamed blood-prostate barrier

Duration ABP: 4–6 weeks

Duration CBP: 4–6 weeks fluoroquinolone or 1–3 months TMP-SMX

Catheter of choice in ABP retention: suprapubic

Image when: no improvement at 48–72 hours → suspect abscess

PSA recheck: 4–6 weeks after prostatitis resolution

NIH-CPSI: validated symptom score for CP/CPPS

UPOINT phenotyping: Urinary, Psychosocial, Organ-specific, Infection, Neurologic, Tenderness — guides multimodal CP/CPPS therapy

Fluoroquinolone black-box: tendinopathy, aortic aneurysm/dissection, peripheral neuropathy, QT, dysglycemia

TMP-SMX risks: hyperkalemia, AKI, SJS, marrow suppression

Granulomatous prostatitis: after intravesical BCG for bladder cancer

Sterile pyuria + prostatitis: consider TB, chlamydia, partially treated infection

Recurrent same-organism UTI in a man: chronic bacterial prostatitis until proven otherwise

Hematospermia + ejaculatory pain: classic CBP feature

Worst complication of ABP: urosepsis, then prostatic abscess

Highest-risk groups for abscess: diabetics, immunocompromised, catheterized

STI partner management: expedited partner therapy where allowed

Avoid in prostatitis: nitrofurantoin (poor prostatic levels), fosfomycin (insufficient evidence), short-course beta-lactams for chronic disease

First-line for retention: alpha-blocker + drainage

Pelvic floor PT: strongest non-pharm evidence for CP/CPPS tenderness phenotype

Phytotherapy with modest evidence: quercetin, cernilton (pollen extract)

Board Question Stem Patterns

Board pearl: When the stem includes "same organism on multiple urine cultures," the answer is CBP and prolonged antibiotic therapy — almost always tested.

Step 3 management: "What is the next best step?" usually hinges on timing — recheck PSA later, image at 72 hours of failure, and follow up culture results in 48–72 hours.

Stem 1 — Classic ABP: 52-year-old man, 2 days of fever, dysuria, perineal pain; DRE reveals exquisitely tender boggy prostate. Best next step? → Urinalysis, urine and blood cultures, start IV ceftriaxone or oral fluoroquinolone based on severity; avoid vigorous prostate massage; treat 4–6 weeks

Stem 2 — Post-biopsy sepsis: Man septic 2 days after transrectal prostate biopsy, urine culture grows fluoroquinolone-resistant E. coli. Best empiric? → Piperacillin-tazobactam or meropenem ± aminoglycoside; ICU if hemodynamic instability

Stem 3 — CBP recognition: Man with three episodes of UTI in past year, same E. coli strain each time, treated with 5-day courses. Best next step? → Diagnose chronic bacterial prostatitis, post-massage urine localization, treat 4–6 weeks fluoroquinolone or 1–3 months TMP-SMX

Stem 4 — Abscess: Diabetic man with ABP, persistent fever on day 3 of IV ceftriaxone. Best next step? → TRUS or CT pelvis to evaluate for prostatic abscess; urology consult for drainage if >1 cm

Stem 5 — Falsely elevated PSA: Man with recent ABP now has PSA 18, asymptomatic 2 weeks post-treatment. Best next step? → Recheck PSA in 4–6 weeks after full resolution, not immediate biopsy

Stem 6 — Retention in ABP: Man with ABP and urinary retention. Catheter of choice? → Suprapubic catheter (transurethral risks bacteremia and trauma)

Stem 7 — Young man with prostatitis: 26-year-old, new partner, dysuria, perineal pain, mildly tender prostate. Best empiric? → Ceftriaxone 500 mg IM + doxycycline 100 mg BID × 7 days (extend for prostatic involvement) covering GC/CT

Stem 8 — CP/CPPS management: Man with 6 months perineal/ejaculatory pain, three negative urine cultures, normal DRE. Best management? → UPOINT-based multimodal therapy: alpha-blocker, pelvic floor PT, neuromodulator, CBT — NOT repeat antibiotics

Stem 9 — Warfarin interaction: Older man with ABP on warfarin started on ciprofloxacin. Best next step? → Check INR within 3–5 days

Stem 10 — Pediatric prostatitis: Prepubertal boy with prostatitis. Best next step? → Renal/bladder ultrasound and VCUG; pediatric urology referral for anatomic anomaly evaluation

Stem 11 — Granulomatous prostatitis: Man with bladder cancer treated with intravesical BCG develops prostatitis. Likely cause? → BCG-related granulomatous prostatitis; manage with urology/ID input

Stem 12 — Sterile pyuria: Prostatitis with sterile pyuria and TB risk factors → GU tuberculosis workup

One-Line Recap

Prostatitis is a four-category NIH spectrum where acute bacterial prostatitis demands prompt cultures and 4–6 weeks of prostate-penetrating antibiotics (fluoroquinolone or TMP-SMX), chronic bacterial prostatitis explains recurrent same-organism UTIs in men and needs the same extended duration, chronic pelvic pain syndrome dominates the chronic category and requires UPOINT-based multimodal therapy rather than repeated antibiotics, and category IV is incidental — with vigilance for abscess, urosepsis, and falsely elevated PSA shaping safe management.

Board pearl: If you remember one thing — men with prostatitis need long antibiotic courses with the right drugs; if you remember two — don't massage a hot prostate, and image when fever persists past 72 hours.

Step 3 management: Master the trio — antibiotic class, duration, and the 48–72 hour follow-up checkpoint — and most prostatitis stems answer themselves.

Recognition rule: Fever + dysuria + tender boggy prostate = ABP; avoid vigorous DRE/massage; obtain cultures and start empiric therapy promptly

Duration rule: Bacterial prostatitis (acute or chronic) needs 4–6 weeks of fluoroquinolone or TMP-SMX — not the 3–7 days of cystitis; beta-lactams alone fail in chronic disease due to poor prostatic penetration

Escalation rule: Failure to improve at 48–72 hours → image for prostatic abscess (TRUS or CT) and consult urology; drain if >1 cm; use suprapubic catheter for retention to avoid bacteremia

Chronic pain rule: CP/CPPS (>90% of chronic cases) is managed by UPOINT phenotyping — alpha-blockers, pelvic floor PT, neuromodulators, CBT, lifestyle — not endless antibiotics; track with NIH-CPSI

Safety rule: Recheck PSA 4–6 weeks after resolution, close the culture follow-up loop within 48–72 hours, and counsel on fluoroquinolone class risks (tendinopathy, aortic, QT, dysglycemia, neuropathy)